TABLE 1

Detection and characterization of PrPSc from selected pigs

Treatment group and animal no.Incubation period (mpi)Overall resultAntigen capture EIA resultWB resultIHC resultPK sensitivityRT-QuIC resultRT-QuIC AFR
CNSaLRSb
Control market wt
    10NTcNAdNANTNTNTNT
    20NTNTNTNTNT
    30NTNTNTNTNT
    46NTNTNTNTNT
    56NA0
Control aged
    625NTNTNTNTNT
    741NTNTNTNTNT
    846NTNTNTNTNT
    973NA0
i.c. inoculated market wt
    100NTNTNTNTNT
    110NTNTNTNTNT
    126++NA+0.031
    136NTNTNTNTNT
    146++NA+0.025
    156+++sensitive0
    166+NA0
    176NTNTNTNTNT
    186++NA+0.120
    196NA0
i.c. inoculated aged
    2030NTNTNTNTNT
    2130NTNTNTNTNT
    2230++NA+0.080
    2330NTNTNTNTNT
    2442+++sensitive+0.030
    2545++++resistant+0.180
    2656++++resistant+0.190
    2764+++resistant+0.170
    2873+++++resistant+0.210
    2973++NA+0.050
Orally inoculated market wt
    326++NA+0.070
    386++NA+0.010
    306+NA0
    366+NA0
    376+NA0
    346NA0
    316NTNTNTNTNT
    336NTNTNTNTNT
    356NTNTNTNTNT
Orally inoculated aged
    3919+NA0
    4041NTNTNTNTNT
    4141++NA+0.029
    4241NTNTNTNTNT
    4345++NA+0.020
    4455++NA+0.030
    4564+++sensitive+0.010
    4665NTNTNTNTNT
    4765NTNTNTNTNT
    4872+NA+0.010
  • a CNS, central nervous system.

  • b LRS, lymphoreticular system.

  • c NT, sample not tested.

  • d NA, result not applicable.